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Antibiotic treatment and associated prolonged
prothrombin time
K J Williams, R P Bax, H Brown, S J Machin
Abstract
The incidence and type of pathology
causing a prolonged prothrombin time
and clinical bleeding episodes were
assessed in a multicentre study of 1109
patients receiving cefotetan, a N-methyl-
thiotetrazole (NMTT), or equivalent
antibiotics. There was no significant dif-
ference in the incidence of a prolonged
prothrombin time (9-9% with cefotetan,
8-0% with comparable antibiotics) of
clinical bleeding episodes. However,
prothrombin time increases of greater
than 12 seconds were significantly (p =
0 002) greater with cefotetan (3-8%) than
with comparators (0-8%). In both
antibiotic groups increases in pro-
thrombin time were more likely follow-
ing surgery and in patients who were
older, with a high platelet count, low
albumin, or higher urea and creatinine
concentrations. All antibiotic treatment
can be associated with prolonged pro-
thrombin times and new agents should
always be assessed in a large multicentre
study before the practical, clinical
importance of haemostatic defects can
be defined.
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There are numerous causes of acquired
defects of the haemostatic mechanism, usually
associated with multisystem disease, or drug
treatment, which are responsible for, or
precipitate, clinical bleeding episodes.'
When such events occur, or are expected, a
series of simple laboratory screening tests,
which are easy to perform and give reliable
results quickly, are routinely undertaken.2
The one stage prothrombin time is an essen-
tial test in all haemostatic screening
procedures and increases of five seconds or
more above the control range, in our
experience, are particularly associated with
clinical bleeding events. For many years
antibiotic treatment has been implicated in
various changes in the normal haemostatic
process and precipitating bleeding.34 Recently
hypoprothrombinaemia and a prolonged
prothrombin time have been specifically
reported in association with several anti-
biotics, particularly cephamandole, moxa-
lactam, and cefoperazone.7 N-methyl-
thiotetrazole (NMTT) containing antibiotics,
such as moxalactam and NMTT alone, inhibit
the vitamin K dependent carboxylation of
glutamic acid residues in liver cells.8
Most clinical reports have emphasised,
however, that a malnourished or debilitated
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condition with relative vitamin K deficiency is
also present before pathological increases in
the prothrombin time and bleeding events
occur.9"' With the background of multisystem
disease and concurrent drug treatment it is
difficult to implicate a single antibiotic in a
specific haemostatic defect such as a prolonged
prothrombin time. To do this, the effects of
sepsis, surgery, and any underlying medical
condition such as renal or liver failure would
have to be separated from those of the
antibiotic itself on prolonging the prothrom-
bin time. Because of these problems there
have been very few controlled studies of
prolonged clotting times associated with
specific antibiotic regimens." Conflicting
evidence has been published about the ability
of relatively new NMTT containing anti-
biotics such as cefotetan to affect the pro-
thrombin time and cause clinically important
bleeding. 12-14
Adverse reports are usually from one or
two isolated cases which are often not
corroborated by independent review. The
importance of this problem has been high-
lighted by the regulatory licensing authorities
insisting that prothrombin time data are now
submitted when clinical trials with cephalo-
sporin antibiotics are being designed and that
reports are filed with all new antibiotics. This
report evaluates how an open, random, com-
parative multicentre study was designed to
investigate the incidence and degree of pro-
thrombin time increases in patients being
treated with intravenous cefotetan, which has
the NMTT side chain, or comparator anti-
biotics, which do not, and the contribution of
any associated risk factors.
Methods
A total of 1109 patients in 19 centres through-
out Europe and South Africa were randomly
chosen to receive either cefotetan (n = 555) or
comparator antibiotic(s) (n = 554), none of
which contained the N-methylthiotetrazole
(NMTT) side chain. The comparators were
those given as standard practice in each centre
and these included cefotaxime (n = 250),
benzyl penicillin or ampicillin/metronidazole
and gentamicin (n = 218), cefoxitin plus
metronidazole (n = 12), cefoxitin (n = 45) and
cephradine plus metronidazole (n = 29).
Children and pregnant women were
excluded from the study and so were patients
with known allergy to cephalosporins or to the
alternative comparative treatment. Patients
receiving other investigational or concurrent
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Table 1 Demographic details of study population
Group taking
cefotetan Group taking
(CTT) comparators
Number of patients 555 554
Sex
Males 248 249
Females 307 303
Mean age (years) 54 54
Age range (years) 14-89 12-93
Site of primary infection
Intra-abdominal 243 235
Urinary tract 117 110
Respiratory tract 61 73
Soft tissue 54 54
Obstetric/gynaecological 64 62
Other 16 20
antimicrobial drugs were excluded. The
demographic data are summarised in table 1.
All patients gave their informed consent for
inclusion in the study and the study protocol
was reviewed by the local ethical committees. A
record form specifically designed for the study
recorded data on factors which were potentially
likely to affect prothrombin time. These
included the history of antibiotics and opera-
tions in the preceding month. Any abnormal
blood loss in this pretreatment period was
recorded along with details of the event, pos-
sible cause, intensity, actions and outcome.
During this period and the trial, details of the
administration of blood or blood products,
vitamin K, warfarin, heparin, parenteral nutri-
tion, non-steroidal anti-inflammatory agents,
steroids, aspirin or other relevant drugs were
recorded.
If vitamin K was administered during the
study it was recorded whether this was part of
routine hospital practice, due to the finding of
an abnormal prothrombin time on admission,
or to an increase during the study period. In all
cases the date of first administration of vitamin
K was also noted. Details of all abnormal blood
loss ofwhatever cause continued to be recorded
during antibiotic treatment and immediately
after treatment. In addition to a routine bio-
chemical profile, full blood count, platelet count
and differential, the one stage prothrombin time
and normal control time were recorded in
seconds. Such tests were performed
immediately before treatment, during and at
the conclusion of treatment, and at follow up,
about 10 days after completion of treatment.
As the prothrombin times were measured in
16 different laboratories using different types of
thromboplastin, the normal range varied be-
tween 11 and 16 seconds. Prolongation of the
prothrombin time was defined as a five second
increase outside the upper limit of the normal
Table 3 Range of significant increases in PT
(percentages are of evaluable patients)
Treatment
Cefotetan Comparators
Range of significant increase N (%) N (%)
No significant increase 454 (90 0) 461 (92 0)
5-12 seconds 31 (6 2) 36 (7-2)
> 12 seconds* 19 (3 8) 4 (0 8)
Total 504 (100-0) 501 (100-0)
*Significantly different (p = 0-002).
range, representing a significant change using
European thromboplastins. In many of the
patients with initially abnormal prothrombin
times or with changes during treatment, a daily
prothrombin time was recorded. Details of
operations performed during treatment were
recorded as well as a full history of all con-
current drugs, especially those known to affect
the prothrombin time such as heparin, war-
farin, and aspirin. The doses of both cefotetan
or comparators were chosen to reflect the
severity and site of the infection.
X2tests were carried out to test whether there
was a significant association between treatment
and incidence ofa prothrombin time increase of
over five seconds and with bleeding events
during the study. The means of the pro-
thrombin time increase for each treatment
group were compared using a t test, because the
mean of any distribution approaches normality
as the number of observations becomes larger.
The t test was also used to detect differences
in prothrombin time increases in the subgroups
with surgery either during or before treatment,
those with an already raised prothrombin time
(more than five seconds), bleeding events before
treatment and those receiving steroids, paren-
teral nutrition, or heparin.
For the multifactorial risk analysis,
laboratory values were converted to the same
units when necessary. Extreme outliers were
found in some of the initial parameters at trial
entry and these were incorporated into equa-
tions at the top of a defined clinically "sensible"
range. In rare cases when a value was missing, a
mean value was inserted. This leads to a smaller
loss of variability than would have occurred if
the patient was omitted, as happens in logistic
regression.
Results
The general condition of the patients and the
severity of the major infection were similar in
the two groups. A total of 883 (79-6%) had not
received any antibiotics in the four weeks
Table 2 Incidence ofprothrombin time changes of overfive seconds
Number of Number with a Percentage
evaluable patients prolongation of > 5 s with > 5 seconds change
CTT Comparators CTT Comparators CTT Comparators
All patients 504 501 50 40 9 9 8-0(3-7-16 1) (2-5-13 5)
Patients with initial PT 79 105 11 9 13-9 8-6
prolonged (7-2-23 6) (40-15 7)
Figures in parentheses are 95% confidence intervals.
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Table 4 Individual variables significantly associated with prothrombin time increase
PT increase PT increase PT increase
Riskfactor < Ss 5-12s > 12s
Operation during antibiotic course
Yes 339 (85 2%) 41 (10-3%) 18 (4 5%)
No 569(948%) 24(40%) 7(12%)
Age (years) Mean (SD) 53-7 (21 7) 58-4 (22-7) 681 (20 2)
Platelets x 109/l Mean (SD) 304 (131) 328 (158) 320 (94)
Albuming/l Mean(SD) 39 1 (11 9) 34-8(10 9) 32-5 (7 9)
Urea mmol/l Mean (SD) 6 2 (3 8) 7-5 (5-4) 13-4 (10-4)
Creatinine smol/l Mean (SD) 99 (42) 106 (50) 166 (71)
Factors significantly associated with a prothrombin change greater than 5 seconds calculated for
all 1005 assessable cases by performing a least squares regression.
Age (p = 00011)
Platelets (p = 0-0462)
Albumin (p = 0 0007)
Urea (p = 0 0001)
Creatinine (p = 0 0001)
No other clinical biochemical or haematological variables were significantly associated with a
prothrombin time increase.
immediately before the study. Only 226
(20-4%) had received other antibiotics in the
four weeks immediately before this study.
Of the 1109 patients randomly selected to
receive either cefotetan (CTT) or comparator
antibiotics, six were withdrawn from the
analysis as they received warfarin with
profound effects on prothrombin time. From
the 1109 patients initially selected, 1005 had
two or more prothrombin times performed. Of
these, 9 5% had two measurements, 26-6% had
three, 56-2% had four and 7-8% had five or
more (the mean was 3-9).
The incidence ofchanges in the prothrombin
time ofover five seconds for all ofthe patients is
shown in table 2. This also shows the subgroup
of patients with an abnormally prolonged
prothrombin time before treatment who
developed further increases ofover five seconds
during treatment. The incidence of increased
prothrombin timewasnot significantly different
between the two groups. When the patients
who developed an increase of prothrombin
time of over 12 seconds are analysed, however,
this is significantly higher in the group taking
cefotetan (p = 0-002) (table 3).
Out of the total of 1109 patients, vitamin K
was only added to 77 patients-A5 patients in
the cefotetan group and 32 in the comparator
group. Of the 77 additions, 27 were as a result
ofnormal practice or an abnormal prothrombin
time before antibiotics were started. In the
remaining 50 cases vitamin K was added as a
result of a rise of prothrombin time (30 taking
cefotetan, 20 taking comparators) during treat-
ment and resulted in a return to normal pro-
thrombin time, and yet some with larger rises
still had no vitamin K added.
An analysis of all of the patient characteris-
tics and laboratory data available showed that
six clinical and laboratory variables were sig-
nificantly related to the development of a
prolonged prothrombin time (table 4).
The incidence of clinical bleeding events
related to antibiotic use and prothrombin time
changes are summarised in table 5. There was
no difference between the incidence of bleeding
events and treatment group, but bleeding was
more common in patients with prolonged
prothrombin times.
Discussion
Although dose ranging studies on standard
haemostasis tests in healthy volunteers are
important in determining the safety profile
during the development of all new antibiotics,
they can give rise to a sense of false security.
Indeed, several volunteer studies showed no
increases in prothrombin time with moxa-
lactam.'5 16 Only when the antibiotic is tested in
large multicentre trials and patients with vary-
ing multisystem disease are given the drug can
the potential effects on the prothrombin time be
assessed properly. Most clinical trials include
too few patients to assess uncommon events.
This large multicentre study showed no sig-
nificant difference in thenumberofsubjectswho
developed a prolonged prothrombin time be-
tween those who received cefotetan alone
(9 9%) or comparator antibiotics (8-0%) des-
pite including 1109 patients. Only when those
patients with increases of 12 seconds or more
(3-8% with cefotetan and 0-8% with com-
parator antibiotics) were analysed was a sig-
nificant difference between the groups found (p
= 0-002). There was no difference in clinical
bleeding episodes between the two antibiotic
treatment groups. The study, however, was
able to show that in both treatment groups
increases ofprothrombin time were more likely
to occur if the patients had an operation, were
older, had a high initial platelet count, a lower
serum albumin concentration, or higher urea
and creatinine concentrations.
Regardless of the precise biochemical
mechanism, malnutrition and vitamin K
deficiency are more common in older patients
with low serum albumin concentrations, and
are likely to be acutely accentuated during
gastrointestinal surgery when little oral
nutrients are received in the first few pre-
operative days.'7 Indeed, these theories have
been proved in a small group of elderly post-
operative patients receiving cefotetan with
clinical features of malnutrition and low serum
vitamin K, concentrations."
Table S Clinical bleeding events
Number ofpatients Number of bleeds Percentage ofpatients
evaluable (during or atfollow up) with bleeds
CTT Comparators CTT Comparators CTT Comparators
No significant increase in PT 454 461 31 26 6-8 5-6(1 7-1 9) (04-10-6)
Increase > 5 seconds 50 40 6 4 12 10(5-24) (3-24)
All patients 504 501 37 30 7-3 6-0(20-12-6) (09-1 1-1)
Note: All bleeds are included irrespective of cause, and 95% confidence limits are given in parentheses.
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Renal impairment, as well as affecting the
elimination of antibiotic, may predispose to
variable coagulation factor deficiencies, hepatic
cell dysfunction, and uraemic enteritis, all of
which can contribute to a prolonged pro-
thrombin time.'9 Studies of the newer agents,
especially the cephamycins, moxalactam, and
cefotetan, have commonly included such com-
promised patients. We have shown, however,
that all antibiotics, especially when given to
patients in the above high risk categories, may
coincidentally be associated with a prolonged
prothrombin time, predisposing in some cases
to clinical bleeding events. Prothrombin time
alone is a poor indicator of vitamin K state and
it may be appropriate to administer vitamin K
to patients with the defined risk factors In
patients without these risks the NMTT con-
taining antibiotic, cefotetan, did not cause
more rises of prothrombin time than alter-
native antibiotics. Single case reports of anti-
biotic associated hypothrombinaemia, which
have been repeatedly reported, must now be
judged against similar control groups receiving
comparative antibiotic treatment. Only when
such data are available can the true incidence
and clinical importance of such events be
judged. The results provided in this paper
should provide guidance regarding the types of
patients in the high risk categories.
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